This phase II trial is trying to determine whether adding an injection to immunotherapy is safe and effective for the treatment of advanced squamous cell carcinomas of the head and neck.
This trial is treating patients with squamous cell carcinoma of the head and neck.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy
Eligible patients will be randomised to receive MK-1454 intratumoural injection plus 200mg of intravenous pembrolizumab, OR receive pembrolizumab alone, for a total treatment duration of up to approximately two years.
Recruiting Hospitals Read More